Carl Zeiss Group

The Carl Zeiss Foundation is the sole shareholder of Carl Zeiss AG, the group's parent company. The foundation is a German non-profit entity established by physicist Ernst Abbe in 1889, which also holds ownership of Schott AG. No individual, family, or external investor holds equity in the Zeiss operating business. This structure was formalized after the firm's post-war division and subsequent reunification in the early 1990s.

Carl Zeiss SMT GmbH is ASML's sole supplier of the optical systems used in its lithography machines, including the mirrors required for extreme ultraviolet (EUV) lithography. ASML acquired a 24.9% stake in Zeiss SMT in 2016 and has committed over €1 billion in joint R&D investment. The relationship is both a supplier-customer partnership and a co-development arrangement that effectively ties the two companies together at the engineering level.

The foundation receives dividends from both Carl Zeiss AG and Schott AG, and is mandated by its charter to distribute those funds to scientific research, university programs, and educational institutions. Specific beneficiaries include German universities with optics and photonics programs, the Max Planck Society, and museums dedicated to the history of optics. The foundation also funds the Ernst Abbe Foundation, which supports endowed chairs and doctoral research.

Zeiss does not operate a publicly named corporate venture capital arm in the style of Intel Capital or Siemens Next47. The group invests primarily through its operating divisions — expanding manufacturing capacity, acquiring precision-engineering firms, and funding internal R&D programs. Its balance sheet also holds industrial real estate across Germany and the United States.

The original Zeiss works in Jena were expropriated by East German authorities in 1948 and operated as VEB Carl Zeiss Jena throughout the Cold War. After reunification in 1990, the East German entity was restructured and a portion of its operations were merged with the West German Carl Zeiss AG, which had been based in Oberkochen since 1946. The Jena site remains an active manufacturing and R&D location for the reunited group.

Semiconductor Manufacturing Technology is the group's largest and most strategically significant division, driven by its relationship with ASML and the global demand for advanced chips. Medical Technology is the second-largest segment, covering surgical microscopes, ophthalmology, and radiotherapy. Industrial Quality & Research and Consumer Markets round out the portfolio, with consumer optics representing the legacy product lines most visible to the public.

The Carl Zeiss Foundation board appoints the supervisory board of Carl Zeiss AG, which in turn appoints the management board led by the CEO. The foundation charter prohibits the sale of the operating company and requires that profits be reinvested in the business or distributed to science. This structure transforms the group into a permanent corporate investor — no exit event, no shareholder liquidity demands, and multi-decade investment horizons.